|
|
Volumn 6, Issue 3, 1995, Pages 356-368
|
|
Docetaxel (Taxotere®), a review of preclinical and clinical experience. Part II: Clinical experience
a
|
|
Author keywords
clinical; docetaxel; efficacy; safety; Taxotere
|
|
Indexed keywords
ANTHRACYCLINE DERIVATIVE;
ANTIHISTAMINIC AGENT;
CISPLATIN;
CORTICOSTEROID;
CYCLOPHOSPHAMIDE;
DOCETAXEL;
DOXORUBICIN;
EPIRUBICIN;
FLUOROURACIL;
GRANULOCYTE COLONY STIMULATING FACTOR;
IFOSFAMIDE;
MITOMYCIN;
VINCA ALKALOID;
ANTINEOPLASTIC AGENT;
DRUG DERIVATIVE;
PACLITAXEL;
TAXOID;
ANTINEOPLASTIC ACTIVITY;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CLINICAL TRIAL;
FLUID RETENTION;
HUMAN;
HYPERSENSITIVITY;
INTRAVENOUS DRUG ADMINISTRATION;
LUNG CANCER;
LUNG NON SMALL CELL CANCER;
MICROTUBULE;
NEUTROPENIA;
OVARY CANCER;
PERIPHERAL NEUROPATHY;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
REVIEW;
NEOPLASM;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
HUMANS;
NEOPLASMS;
PACLITAXEL;
TAXOIDS;
|
|
EID: 0028989720
PISSN: 09594973
EISSN: None
Source Type: Journal
DOI: 10.1097/00001813-199506000-00002 Document Type: Review |
|
Times cited : (125)
|
|
References (0)
|
